Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report

Bearz, Alessandra; Santarossa, Sandra; Manfre, A.; Beltrame, G.; Urbani, Martina; Sartor, Ivana; Ros, Valentina Da; Tirelli, Umberto

doi:10.1186/1756-0500-7-589

Cited by 9 publications

(3 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are some studies in the form of more case reports, especially on adenocarcinoma, and it is reported that it responds well to various chemotherapies. In particular, tyrosine kinase inhibitors such as bevacizumab, gefitinib, erlotinib, crizotinib and pemekrexet are more effective chemotherapy drugs in adenocancer (10,11).…”

Section: Discussionmentioning

confidence: 99%

Lung cancer and choroidal metastase

Selen¹,

ÜNSAL²,

SERASLAN³

2023

J Exp Clin Med

View full text Add to dashboard Cite

Sixty-nine-year-old male patient, having treatment after one month due to lung adenocancer, was admitted to our clinic with the complaint of blurred vision in the left eye. Fundoscopy examination revealed irregular macula in both eyes and metastasis in both eyes choroid in Optical Coherence Tomography (OCT). In our case, it was observed that although both eye choroids had metastasized, the complaints of the eyes were lost with radiotherapy.In this case, after the completion of chemotherapy for lung cancer, a patient who developed eye metastasis during follow-up, did not respond to treatment and whose symptoms were improved with radiotherapy, was presented.

show abstract

Section: Discussionmentioning

confidence: 99%

Lung cancer and choroidal metastase

Selen¹,

ÜNSAL²,

SERASLAN³

2023

J Exp Clin Med

View full text Add to dashboard Cite

show abstract

“…She started alectinib treatment and both her ocular and systemic symptoms were palliated in a week. Bearz.A et al.reported the case of a patient with choroidal metastasis in progression in the right lung and mediastinal lymph nodes after 15 months of crizotinib treatment, and then switched to oral aletinib and went into remission after 7 months ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report

Liu

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Choroidal metastasis as an initial presenting feature of lung cancer with EML4-ALK translocation is exceedingly rare and greatly impacts patient quality of life (QOL). There are no recommended treatments for such patients, and palliative care remains limited. It is unclear whether surgical resection of primary pulmonary lesions, systemic antitumor therapy, targeted therapy, or localized ocular therapy are effective in treating choroidal metastases in EML4-ALK rearranged oligometastatic non-small cell lung cancer (NSCLC). Here, we present the case of choroidal metastases secondary to lung cancer and EML4-ALK translocation in a 57-year-old woman who firstly underwent resection of lung lesions followed by oral administration of crizotinib without local treatment or systemic chemotherapy. Since then she had a rapid and complete response to crizotinib with 27 months of progression-free survival.

show abstract

“…10 In 2014, the first case of choroidal metastasis responding to crizotinib without previous radiotherapy was reported. 11 Lu et al presented a patient with receptor tyrosine kinase 1-rearranged NSCLC who presented with a choroidal metastasis that did not respond to the initial chemotherapy but had a rapid and complete response to crizotinib. 12 Cui et al report a case that did have an initial response to crizotinib but after 16 months of crizotinib developed resistance with a new choroidal metastasis.…”

Section: Discussionmentioning

confidence: 99%

Effective Treatment of Choroidal Metastasis With ALK Inhibitor Chemotherapy That Crosses the Blood–Brain Barrier

Possin

Altaweel

2018

Journal of VitreoRetinal Diseases

View full text Add to dashboard Cite

We report a case of metastatic non-small cell lung cancer (NSCLC) with choroidal metastasis, which responded to oral ensartinib. Methods: Retrospective case report on a 44-year-old male with a past medical history significant for metastatic NSCLC with a positive anaplastic lymphoma kinase (ALK) translocation that was treated for 4 years with oral crizotinib systemically, and bevacizumab intravitreal injections for management of subretinal fluid associated with a left macular choroidal metastasis. The vision was maintained at 20/25 to 20/40, but there was steady growth in the breadth and thickness of the choroidal lesion. Results: Two months after starting daily oral ensartinib, his vision improved from 20/40 to 20/20. His lesion decreased significantly in size, with resolution of his subretinal fluid, and has not required any additional bevacizumab intravitreal injections in the 8 months since starting ensartinib. Conclusion: Ensartinib may be beneficial in the treatment of choroidal metastases in patients with NSCLC with ALK mutations.

show abstract

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report

Cited by 9 publications

References 8 publications

Lung cancer and choroidal metastase

Lung cancer and choroidal metastase

Effective Systemic Treatment of Choroidal Metastases NSCLC With Surgery After Crizotinib: A Case Report

Effective Treatment of Choroidal Metastasis With ALK Inhibitor Chemotherapy That Crosses the Blood–Brain Barrier

Contact Info

Product

Resources

About